Novartis this morning cut its full-year sales forecasts saying that generic competition in the USA will affect the second half performance of its blood-pressure-lowering drug Lotrel (almodipine/benazepril) and the antifungal Lamisal (terbinafine), while it also expects to see some fallout following the market withdrawal of the irritable bowel syndrome drug Zelnorm (tegaserod) after it was linked to possible heart attacks and strokes.
The three products combined reeled in 2006 sales of $2.5 billion.
No comments:
Post a Comment